ArticleDiabetes, obesity & metabolism2025
Declining incidence of hypoglycaemia in diabetes secondary to chronic pancreatitis: A nationwide cohort study from 2003 to 2022.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Declining incidence of hypoglycaemia in diabetes secondary to chronic pancreatitis: A nationwide cohort study from 2003 to 2022.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsPopulation-based studies have consistently shown that individuals with diabetes secondary to chronic pancreatitis (pancreatic diabetes) have a high risk of hypoglycaemia. We aimed to investigate whether this risk has declined over recent years following the introduction of modern glucose-lowering medications. MATERIALS AND
methodsIn this Danish nationwide population-based cohort study, we included all adults with new-onset diabetes between 1998 and 2022 and classified them as having pancreatic diabetes, type 1, or type 2 diabetes. We examined annual incidence rates of hypoglycaemia leading to hospitalisation, trends in dispensed glucose-lowering medications, and associations with hypoglycaemia risk.
resultsAmong 583 220 individuals with new-onset diabetes, 3383 (0.6%) were classified as pancreatic diabetes, 12 383 (2.1%) as type 1 diabetes, and 567 454 (97.3%) as type 2 diabetes. Comparing 2003-2006 to 2019-2022, the incidence of severe hypoglycaemia declined within each diabetes subtype: by 69% in pancreatic diabetes (incidence rate ratio (IRR) 0.33, 95% CI 0.25-0.40), 57% in type 1 diabetes (IRR 0.43, 95% CI 0.38-0.49), and 65% in type 2 diabetes (IRR 0.35, 95% CI 0.33-0.37). This coincided with a shift from human to analogue insulin and an increase in the use of metformin in individuals with pancreatic diabetes. Metformin use was associated with a lower risk of severe hypoglycaemia (adjusted hazard ratio 0.36, 95% CI 0.26-0.48). All types of insulin were associated with higher hypoglycaemia risk; insulin analogues carried a lower risk than human insulin.
conclusionHospitalisation for hypoglycaemia in pancreatic diabetes has declined substantially over time, alongside notable changes in treatment patterns.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.